Literature DB >> 19809306

Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.

Patrick Van Dreden1, Aurélie Rousseau, Arnaud Savoure, Bernard Lenormand, Sylvianne Fontaine, Marc Vasse.   

Abstract

Several studies have indicated an association between haemostatic markers and acute myocardial infarction, but few or no studies refer to their activity. We studied plasma levels of 10 coagulation factors (fibrinogen, protein C, protein S, von Willebrand factor, D-dimers, factor VIIa, free tissue factor pathway inhibitor, tissue-type plasminogen activator, plasminogen activator inhibitor-1, thrombomodulin) and using new specific assays analysed the activity of plasma tissue factor (TFa), thrombomodulin (TMa), and procoagulant phospholipid in 46 consecutive patients with acute myocardial infarction at the time of hospital admission, and compared them with 34 healthy normal volunteers. Plasma levels of TFa, TMa, and procoagulant phospholipid were significantly higher in cases than in control patients (P < 0.001). In addition the ratio of TFa/free tissue factor pathway inhibitor was higher in patients than in controls, whereas the tissue-type plasminogen activator (t-PA)/plasminogen activator inhibitor-1 ratio was lower in patients. Interestingly, patients with an unfavourable outcome during a 2-month follow-up had higher levels of TFa, TMa, procoagulant phospholipid, a higher ratio of TFa/free tissue factor pathway inhibitor and a lower ratio of t-PA/plasminogen activator inhibitor-1 than patients who recovered. The combination of these different parameters reveals an increase in procoagulant activity as well as impaired fibrinolytic activity during the acute phase of an acute myocardial infarction. The association of the level of the activity of these three factors may provide a new tool to assess the prognosis of acute myocardial infarction. Further studies are needed to support our findings and to elucidate the clinical interest of measuring these factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809306     DOI: 10.1097/MBC.0b013e32832e05dd

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  13 in total

1.  Markers of inflammation and coagulation may be modulated by enteral feeding strategy.

Authors:  Julie A Bastarache; Lorraine B Ware; Timothy D Girard; Arthur P Wheeler; Todd W Rice
Journal:  JPEN J Parenter Enteral Nutr       Date:  2012-02-07       Impact factor: 4.016

Review 2.  Microparticles in hemostasis and thrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

3.  Procoagulant activity, but not number, of microparticles increases with age and in individuals after a single venous thromboembolism.

Authors:  B A L Owen; A Xue; J A Heit; W G Owen
Journal:  Thromb Res       Date:  2010-11-23       Impact factor: 3.944

Review 4.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

5.  Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Authors:  Konstantinos Syrigos; Dimitra Grapsa; Rabiatou Sangare; Ilias Evmorfiadis; Annette K Larsen; Patrick Van Dreden; Paraskevi Boura; Andriani Charpidou; Elias Kotteas; Theodoros N Sergentanis; Ismail Elalamy; Anna Falanga; Grigoris T Gerotziafas
Journal:  Oncologist       Date:  2018-08-13

6.  HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.

Authors:  Barry W Festoff; Ravi K Sajja; Patrick van Dreden; Luca Cucullo
Journal:  J Neuroinflammation       Date:  2016-08-24       Impact factor: 8.322

7.  Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study.

Authors:  Grigoris T Gerotziafas; Patrick Van Dreden; Emmanuelle Mathieu d'Argent; Eleftheria Lefkou; Matthieu Grusse; Marjorie Comtet; Rabiatou Sangare; Hela Ketatni; Annette K Larsen; Ismail Elalamy
Journal:  Thromb J       Date:  2017-03-28

8.  Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.

Authors:  Despina Fotiou; Theodoros N Sergentanis; Loula Papageorgiou; Kimon Stamatelopoulos; Maria Gavriatopoulou; Efstathios Kastritis; Theodora Psaltopoulou; Stella Salta; Patrick Van Dreden; Rabiatou Sangare; Annette K Larsen; Evangelos Terpos; Ismail Elalamy; Meletios A Dimopoulos; Grigoris T Gerotziafas
Journal:  Blood Cancer J       Date:  2018-11-07       Impact factor: 11.037

9.  Procoagulant phospholipids and tissue factor activity in cerebrospinal fluid from patients with intracerebral haemorrhage.

Authors:  Patrick Van Dreden; Guy Hue; Jean-François Dreyfus; Barry Woodhams; Marc Vasse
Journal:  Adv Hematol       Date:  2014-02-17

Review 10.  Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration.

Authors:  Barry W Festoff; Ravi K Sajja; Luca Cucullo
Journal:  Biomed Res Int       Date:  2017-08-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.